---
title: "AstraZeneca CFO Sarin gains 73 shares from 2021 performance share plan dividend equivalents"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299064766.md"
description: "AstraZeneca disclosed that CFO Aradhana Sarin acquired 73 ordinary shares on September 14, 2026. These shares originated from dividend equivalent awards tied to the company's 2021 Performance Share Plan. The fair market value for tax purposes was GBP 114.60 per share at vesting, based on the prior trading day’s closing price."
datetime: "2026-09-15T14:25:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299064766.md)
  - [en](https://longbridge.com/en/news/299064766.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299064766.md)
generator: "portal-rs"
---

# AstraZeneca CFO Sarin gains 73 shares from 2021 performance share plan dividend equivalents

-   AstraZeneca disclosed a share-based award outcome for CFO Aradhana Sarin under its 2021 Performance Share Plan. \* Sarin acquired 73 ordinary shares on Sept. 14, 2026 from separately vesting dividend equivalent awards tied to the 2021 plan. \* Fair market value used for tax purposes was GBP 114.60 per share at vest, based on the prior trading day’s close. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-008369), on September 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective](https://longbridge.com/en/news/298875452.md)
- [Key facts: AstraZeneca (AZN) NICE OK Enhertu; FDA review; China plan](https://longbridge.com/en/news/299411391.md)
- [AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears](https://longbridge.com/en/news/298828016.md)
- [AstraZeneca's breast cancer drug fails in late-stage trial](https://longbridge.com/en/news/298768423.md)
- [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**